Lilly’s tirzepatide will be biggest blockbuster ever, topping $70B by 2032: Evaluate

Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.